Zanidatamab + chemotherapy, with or without tislelizumab, may increase survival in metastatic or locally advanced gastroesophageal adenocarcinoma ...
First-line zanidatamab plus chemotherapy leads to ‘practice-changing’ PFS and overall survival gains in a phase 3 study of ...
Forget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz ...
In March 2025, The FDA awarded orphan drug designation to Nerlynx® (neratinib) for treating breast cancer patients with brain ...
Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany– 12 January, ...
Pyrotinib in the first-line treatment of HER2-positive advanced breast cancer: Results from the PRETTY study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...
Tukysa (tucatinib) may represent a new patient-friendly option as a first line maintenance treatment possibility for patients ...
SurvivorNet on MSN
Enhertu significantly cuts recurrence rates for women with high-risk HER2-positive breast cancer — the practice-changing DESTINY-Breast05 trial
DESTINY-Breast05 is a large phase 3 trial in women with HER2-positive early-stage breast cancer who had chemotherapy and ...
Positive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line ...
Zanidatamab shows promise in extending survival for patients with HER2-positive biliary tract cancer, marking a significant ...
Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).
HER2CLIMB-05 trial evaluated Tukysa in combination with Herceptin and Perjeta for HER2-positive metastatic breast cancer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback